You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523SBC: SignalRx Pharmaceuticals Inc. Topic: 102
There is an unmet need to inhibit the key cancer promoting transcription factor MYCboth c MYC and MYCNthat act downstream of many cell receptors and signal transcription pathways to activate genes for cancer cell resistance and tumor growthTo datesmall molecule inhibitors of MYC have remained elusiveIn our Phase I STTRCAwe developed a lead compoundSFwhich displays potent orthogonal inhibitory acti ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
Advanced Assessment to Accelerate Diagnostic Skill Acquisition, Phase IISBC: Parallel Consulting, LLC Topic: 300
Project Summary Today s clinical learning environments do not provide the level of deliberate practicedirect supervisionand rigorous assessment and feedback needed to develop diagnostic reasoning expertiseClinical performance assessment emphasizes learner evaluation over learner developmentlacks rigor and utility for developmental purposesand clinical teachers have expressed particular difficulty ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
The nGoggle: A portable brain-based device for assessment of visual function deficitsSBC: NGOGGLE INC Topic: N
PROJECT SUMMARY Assessment of loss of visual function outside the foveal area is an essential component of the management of numerous conditionsincluding glaucomaretinal and neurological disordersDespite the significant progress achieved with the development of standard automated perimetrySAPmany decades agoassessment of visual field loss with SAP still has significant drawbacksSAP testing is limi ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
Development of Pirenzepine for CIPNSBC: WinSanTor, Inc. Topic: NCI
PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
A nanoparticle delivery system for CRISPR/Cas9 based therapeuticsSBC: ATGC Inc. Topic: 100
Abstract Applications of customizable nucleases such as CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteinhave enabled efficient and precise gene correction in vitroand hold promises for eventually achieving in vivo gene correction therapyHoweverto apply CRISPR Casin therapeutic settingsseveral major challenges remain to be addressedihomologous recombinatio ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetesSBC: REMD BIOTHERAPEUTICS INC Topic: NIDDK
DESCRIPTIONprovided by applicantFast TrackInsulin remains the primaryand often the onlytreatment for typediabetes mellitusT DHowever it is associated with chronic iatrogenic hyperinsulinemiasecondary hyperlipidemiahigher incidence and severity of cardiovascular complicationsand life threatening hypoglycemia eventsA higher mortalityvsdue to cardiovascular complications were reported in insulin trea ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
Testing a male oral contraceptive targeting EppinSBC: EPPIN PHARMA INC Topic: NICHD
The global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
Comprehensive Glycoproteomic Tool Development for Cancer BiomarkersSBC: PROTEIN METRICS INC Topic: 400
Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health